Lilly Asia Ventures
Zhihui Wang, Ph.D., is an Investment Manager with Lilly Asia Ventures (LAV). Prior to joining LAV, she worked at Boston Consulting Group (BCG) Shanghai office as a core member of Healthcare Practice, supporting pharma/biotech and VC/PE firms on various corporate strategy and investment-related topics. Zhihui holds Ph.D. in Population Health Sciences from Harvard University and B.M. in Preventive Medicine from Fudan University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.